Literature DB >> 26598521

Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis.

Wan Yee Leong1, Hong Guo1, Ou Ma1, Hui Huang2, Alan B Cantor2, Alan D Friedman3.   

Abstract

Src phosphorylates Runx1 on one central and four C-terminal tyrosines. We find that activated Src synergizes with Runx1 to activate a Runx1 luciferase reporter. Mutation of the four Runx1 C-terminal tyrosines to aspartate or glutamate to mimic phosphorylation increases trans-activation of the reporter in 293T cells and allows induction of Cebpa or Pu.1 mRNAs in 32Dcl3 myeloid cells, whereas mutation of these residues to phenylalanine to prevent phosphorylation obviates these effects. Three mechanisms contribute to increased Runx1 activity upon tyrosine modification as follows: increased stability, reduced histone deacetylase (HDAC) interaction, and increased DNA binding. Mutation of the five modified Runx1 tyrosines to aspartate markedly reduced co-immunoprecipitation with HDAC1 and HDAC3, markedly increased stability in cycloheximide or in the presence of co-expressed Cdh1, an E3 ubiquitin ligase coactivator, with reduced ubiquitination, and allowed DNA-binding in gel shift assay similar to wild-type Runx1. In contrast, mutation of these residues to phenylalanine modestly increased HDAC interaction, modestly reduced stability, and markedly reduced DNA binding in gel shift assays and as assessed by chromatin immunoprecipitation with the -14-kb Pu.1 or +37-kb Cebpa enhancers after stable expression in 32Dcl3 cells. Affinity for CBFβ, the Runx1 DNA-binding partner, was not affected by these tyrosine modifications, and in vitro translated CBFβ markedly increased DNA affinity of both the translated phenylalanine and aspartate Runx1 variants. Finally, further supporting a positive role for Runx1 tyrosine phosphorylation during granulopoiesis, mutation of the five Src-modified residues to aspartate but not phenylalanine allows Runx1 to increase Cebpa and granulocyte colony formation by Runx1-deleted murine marrow.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Runx1; Src; hematopoiesis; histone deacetylase (HDAC); myeloid cell; transcription factor; tyrosine kinase

Mesh:

Substances:

Year:  2015        PMID: 26598521      PMCID: PMC4705401          DOI: 10.1074/jbc.M115.674234

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

Review 1.  Leukemogenesis by CBF oncoproteins.

Authors:  A D Friedman
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

2.  Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development.

Authors:  Ichiro Taniuchi; Motomi Osato; Takeshi Egawa; Mary Jean Sunshine; Suk Chul Bae; Toshihisa Komori; Yoshiaki Ito; Dan R Littman
Journal:  Cell       Date:  2002-11-27       Impact factor: 41.582

3.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 4.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

5.  Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation.

Authors:  G Huang; K Shigesada; K Ito; H J Wee; T Yokomizo; Y Ito
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

6.  Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.

Authors:  Gordon Chan; Laurene S Cheung; Wentian Yang; Michael Milyavsky; Ashley D Sanders; Shengqing Gu; Wan Xing Hong; Aurora X Liu; Xiaonan Wang; Mary Barbara; Tarun Sharma; Joehleen Gavin; Jeffery L Kutok; Norman N Iscove; Kevin M Shannon; John E Dick; Benjamin G Neel; Benjamin S Braun
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

7.  The Fes tyrosine kinase: a signal transducer that regulates myeloid-specific gene expression through transcriptional activation.

Authors:  Jynho Kim; Yoshiyasu Ogata; Humayra Ali; Ricardo A Feldman
Journal:  Blood Cells Mol Dis       Date:  2004 Mar-Apr       Impact factor: 3.039

8.  The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1.

Authors:  Yoichi Imai; Mineo Kurokawa; Yuko Yamaguchi; Koji Izutsu; Eriko Nitta; Kinuko Mitani; Masanobu Satake; Tetsuo Noda; Yoshiaki Ito; Hisamaru Hirai
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

9.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Takashi Asai; Toshiki Saito; Sachiko Seo; Ieharu Yamazaki; Tetsuya Yamagata; Kinuko Mitani; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa; Hisamaru Hirai
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

10.  The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.

Authors:  Kristie L Durst; Bart Lutterbach; Tanawan Kummalue; Alan D Friedman; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

View more
  5 in total

1.  RUNX1 cooperates with FLT3-ITD to induce leukemia.

Authors:  Kira Behrens; Katrin Maul; Nilgün Tekin; Neele Kriebitzsch; Daniela Indenbirken; Vladimir Prassolov; Ursula Müller; Hubert Serve; Jörg Cammenga; Carol Stocking
Journal:  J Exp Med       Date:  2017-02-17       Impact factor: 14.307

Review 2.  RUNX1 Dosage in Development and Cancer.

Authors:  Michael Lie-A-Ling; Renaud Mevel; Rahima Patel; Karen Blyth; Esther Baena; Valerie Kouskoff; Georges Lacaud
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 4.250

Review 3.  Role of HDACs in normal and malignant hematopoiesis.

Authors:  Pan Wang; Zi Wang; Jing Liu
Journal:  Mol Cancer       Date:  2020-01-07       Impact factor: 27.401

Review 4.  Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies.

Authors:  Zi Wang; Pan Wang; Yanan Li; Hongling Peng; Yu Zhu; Narla Mohandas; Jing Liu
Journal:  Signal Transduct Target Ther       Date:  2021-01-20

5.  PAK4 phosphorylating RUNX1 promotes ERα-positive breast cancer-induced osteolytic bone destruction.

Authors:  Lina Tang; Yunling Gao; Yongqi Song; Yang Li; Yanshu Li; Hongyan Zhang; Danni Li; Jiabin Li; Caigang Liu; Feng Li
Journal:  Int J Biol Sci       Date:  2020-05-25       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.